ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite the fact that imatinib is a highly promising agent for treating CML, its therapeutic potential is limited due to amplification of the BCR–ABL gene or emergence of point mutations in BCR–ABL [7].